|1.||WO||WO/2013/033656 - METHODS FOR THE TREATMENT OF BREAST CANCER||07.03.2013||
|PCT/US2012/053551||SYNDAX PHARMACEUTICALS, INC.||GOODENOW, Robert|
Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
|2.||WO||WO/2012/123768 - DISPENSING OF FIZZY BEVERAGES UNDER COUNTER - PRESSURE||20.09.2012||
|PCT/GE2011/000005||PERTIA, Shota||PERTIA, Shota|
The invention relates to an appliance for dispensing fizzy beverages into bottles, mugs or glasses under counter-pressure. In a first step the beverage container is mounted to the appliance in a pressure-proof chamber and then the container is pressurised by connecting it to a source of inert gas. During the filling of the container with beverage, the gas pressure is controlled in order to maintain it within given limits. The gas which is displaced by the beverage is fed to an expansion tank.
|3.||WO||WO/2012/125012 - METHOD FOR NOTIFICATION OF A CALLED SUBSCRIBER IN THE ABSENCE OF SUFFICIENT CREDIT OF THE CALLING PARTY||20.09.2012||
|PCT/MD2012/000001||NICOLAESCU, Gheorghe||NICOLAESCU, Gheorghe|
The invention relates to telephone communication, in particular to methods for notification of the called subscriber in the communication networks, namely in the absence of the calling party's valid credit account, and can be used in existing mobile telecommunications systems, including GSM, 3 GSM, 3G, CDMA, WCDMA, and others. In the method each subscriber of the network is provided with an opportunity to get network access for outgoing calls, regardless of the status of his/her account, and to accept the call and/or receive the calling subscriber's messages without the pre-paid credit account. The calling subscriber dials the phone number of the called subscriber; the operator of the calling subscriber determines his solvency; upon initiation of a call by the calling subscriber, who does not have a valid credit account, for its transmission to the called subscriber the outgoing call is directed through the operator serving the calling subscriber to a forwarding and controlling server and at its command disconnects the calling subscriber. The forwarding and controlling server processes the obtained information and forms a transit call, by the transit call through the operator serving the calling subscriber is transferred an outgoing call to the operator's network serving the called subscriber as an information call, notifying of the missed call. A notification about the missed call is created for the called subscriber, providing information about the calling subscriber, and the information call is disconnected after its receipt by the called subscriber. The result, obtained by means of the claimed method, consists in increasing the reliability and ease of communication between subscribers in an irregular situation, namely upon insolvency of the calling subscriber.
|4.||WO||WO/2012/114222 - IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS||30.08.2012||
|PCT/IB2012/050589||PFIZER INC.||CHAPPIE, Thomas Allen|
The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.
|5.||WO||WO/2012/113999 - PROCESS AND INTERMEDIATES FOR SYNTHESIZING AGOMELATINE||30.08.2012||
|PCT/FR2012/000005||LES LABORATOIRES SERVIER||ZARD, Samir|
A process for the industrial synthesis of the compound of formula (I) from the allyl cyanide of formula (II) and a compound of formula (III), wherein Xa is an -S-C(S)-OR group in which R is a linear or branched (C1-C6) alkyl group.
|6.||WO||WO/2012/102688 - SUBSIDENCE CONTROL SYSTEM||02.08.2012||
|PCT/US2010/057162||RED LEAF RESOURCES, INC.||PATTEN, James, W.|
A method of maintaining structural integrity of a subsiding earthen fluid containment structure is disclosed and comprises forming a lined containment infrastructure (100) including a convex bulged crown portion (120), floor portion (110) and sidewall portions (115) which enclose a comminuted earthen material (126) within an enclosed volume (125) such that fluid flow from the lined containment compound is restricted. The bulged crown flattens, thickens and diminishes in surface area during subsidence of the comminuted earthen material as fluid is removed. The bulged crown is shaped to avoid tensile stresses which may otherwise result in breach or failure of lined containment during subsidence. Further, the lined containment structure can include an inner insulative layer and an outer impermeable seal layer having unique contributions as described in more detail herein.
|7.||WO||WO/2012/095549 - DEVICE AND METHOD FOR PURIFYING AIR FROM NON-DESIRED COMPONENTS AND FOR ELIMINATING SUCH COMPONENTS||19.07.2012||
|PCT/FI2011/000037||AAVI TECHNOLOGIES LTD||ILMASTI, Veikko Ilmari|
This invention concerns a device for purifying air from non-desired gases and particles, in the case of nuclear power plants from radiating particles and gaseous iodine, as well as for extermination of microorganisms and removal from the air. The device consists of a purifying chamber through which the air to be purified is arranged to flow. In the structurally grounded purifying chamber ionized air (1) is led to a water dust or vapor which can be oxidized for instance by means of hydrogen peroxide (6) and by increasing the voltage level of the ionization in order to produce ozone and to be led further to high voltage operated ion blast tips (8) producing a continuous ion jet, which is directed onto collecting surfaces (9) and taking with it both droplets and particulate materials as well as gaseous components connected to them. The volume of the air to be purified determines the shape and volume of the purifying device. In use also energy saving is very significant compared to fiber filtration.
|8.||WO||WO/2012/092612 - ANTI-CD38 ANTIBODIES||05.07.2012||
|PCT/US2011/068235||TAKEDA PHARMACEUTICAL COMPANY LIMITED||ELIAS, Kathleen Ann|
Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
|9.||WO||WO/2012/091153 - ORALLY DISINTEGRATING TABLET||05.07.2012||
|PCT/JP2011/080568||TAKEDA PHARMACEUTICAL COMPANY LIMITED||ISHII, Shiro|
Provided is an orally disintegrating tablet obtained by tableting fine granules showing controlled release of lansoprazole and an additive, which is capable of suppressing breakage of the fine granules during tableting, and can control the release of lansoprazole for a long time, and can maintain a therapeutically effective concentration for a prolonged time, and shows superior disintegration property in the oral cavity. An orally disintegrating tablet containing (i) fine granules showing controlled release of a pharmaceutically active ingredient, which contains fine granules containing a pharmaceutically active ingredient and a coating layer containing a methacrylic acid/methyl acrylate/methyl methacrylate copolymer, wherein the fine granules containing a pharmaceutically active ingredient are coated with more than 80 wt% and not more than 300 wt% of the copolymer, and (ii) fine granules showing controlled release of a pharmaceutically active ingredient, which contains the pharmaceutically active ingredient and a coating layer comprising (a) an ethyl acrylate/methyl methacrylate copolymer, and (b) one or more kinds of polymers selected from the group consisting of methacrylic acid/ethyl acrylate copolymer, hypromellose phthalate, carboxymethylethylcellulose, polyvinyl acetate phthalate, hydroxypropyl methylcellulose acetate succinate and cellulose acetate phthalate, wherein the fine granules (i) and fine granules (ii) have an average particle size of not more than 500 micrometer, and the pharmaceutically active ingredient is lansoprazole or an optically active form thereof or a salt thereof.
|10.||WO||WO/2012/090994 - OPHTHALMIC SOLUTION CONTAINING DIQUAFOSOL, METHOD FOR PRODUCING SAME, AND METHOD FOR PREVENTING FORMATION OF INSOLUBLE PRECIPITATE||05.07.2012||
|PCT/JP2011/080179||SANTEN PHARMACEUTICAL CO., LTD.||SAKATANI, Akiko|
An ophthalmic solution containing diquafosol to which a chelating agent is added, wherein the formation of an insoluble precipitate during storage and a lowering in filtration performance in a production process (a filtration/sterilization process), said insoluble precipitate formation and said lowering in filtration performance being observed in conventional ophthalmic solutions containing diquafosol, are inhibited. It is also confirmed that the ophthalmic solution containing diquafosol to which a chelating agent is added shows an improved ability to retain the effect during storage. Therefore, the present invention provides an ophthalmic solution containing diquafosol, said ophthalmic solution having stable physicochemical properties in the course of production, distribution and storage by a patient, in particular, enabling efficient filtration/sterilization in the production process, and, moreover, having an excellent ability to retain the effect during storage. Also, the present invention provides a method for preventing the formation of an insoluble precipitate from an aqueous ophthalmic solution containing diquafosol or a salt thereof, said method comprising adding a chelating agent to the aqueous ophthalmic solution.